Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer
J. Vlaar, A. Borgman, E. Kalkhoven, D. Westland, N. Besselink, C. Shale, B. M. Faltas, P. Priestley, E. Kuijk, E. Cuppen
This study identifies AHR{Delta}e8-9 as a novel driver mutation in urinary tract cancer, leading to ligand-independent pathway activation and tumorigenic properties in bladder organoids.
bioRxiv · Nov 9, 2021Cancer Biology